Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Phase 0 Completed 10 enrolled Mayo Clinic GlaxoSmithKline · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.

Timeline

Start: 2019-07-30
Primary completion: 2023-11-15
Completion: 2025-02-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mepolizumab	Monoclonal antibody	200 mg	Subcutaneous

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Summary

Timeline

Drugs

Indications